Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer ; volume:12 ; number:1 ; day:28 ; month:2 ; year:2012 ; pages:1-12 ; date:12.2012
BMC cancer ; 12, Heft 1 (28.2.2012), 1-12, 12.2012
- Creator
-
Magbanua, Mark Jesus M.
- Contributor
-
Sosa, Eduardo V.
Scott, Janet H.
Simko, Jeff
Collins, Colin
Pinkel, Dan
Ryan, Charles J.
Park, John W.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-78
- URN
-
urn:nbn:de:1111-201603045450
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Magbanua, Mark Jesus M.
- Sosa, Eduardo V.
- Scott, Janet H.
- Simko, Jeff
- Collins, Colin
- Pinkel, Dan
- Ryan, Charles J.
- Park, John W.
- SpringerLink (Online service)
Other Objects (12)
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)